https://www.ovid.com/jnls/cnmo/fulltext/10.1097/nm9.0000000000000092~implementing-212-pb-targeted-alpha-therapy-a-safety-first If you had a ๐ง๐๐ฎ๐ซ๐จ๐๐ง๐๐จ๐๐ซ๐ข๐ง๐ ๐ญ๐ฎ๐ฆ๐จ๐ซ ๐ข๐ง ๐ฒ๐จ๐ฎ๐ซ ๐ฌ๐ญ๐จ๐ฆ๐๐๐ก, ๐ฌ๐ฆ๐๐ฅ๐ฅ ๐ข๐ง๐ญ๐๐ฌ๐ญ๐ข๐ง๐, ๐๐ฉ๐ฉ๐๐ง๐๐ข๐ฑ, ๐๐จ๐ฅ๐จ๐ง, ๐ฉ๐๐ง๐๐ซ๐๐๐ฌ, ๐ฅ๐ฎ๐ง๐ ๐ฌ, ๐๐๐ซ๐๐ง๐๐ฅ ๐ ๐ฅ๐๐ง๐๐ฌ, ๐ญ๐ก๐ฒ๐ซ๐จ๐ข๐, ๐ฉ๐ข๐ญ๐ฎ๐ข๐ญ๐๐ซ๐ฒ, ๐ซ๐๐๐ญ๐ฎ๐ฆ, ๐๐ซ๐๐๐ฌ๐ญ, ๐จ๐ซ ๐ฉ๐ซ๐จ๐ฌ๐ญ๐๐ญ๐, ๐ฐ๐จ๐ฎ๐ฅ๐ ๐ฒ๐จ๐ฎ ๐ฐ๐๐ง๐ญ ๐ญ๐จ ๐ญ๐ซ๐ฒ ๐ ๐ซ๐๐๐ข๐จ๐๐๐ญ๐ข๐ฏ๐ ๐๐ซ๐ฎ๐ ย as (a small) part of the treatment? The emerging clinical dataset highlights excellent short-term tolerability for 212Pb-TAT, with adverse events primarily consisting of low-grade […]
Archive for August 11th, 2026
If you had a neuroendocrine tumor, would you be willing to try a radioactive drug as a small part of your treatment?
Posted by Michael A. S. Guth on August 11th, 2026



Posted in